Sort
10,766 grants matching “checkpoint inhibitor”
Inhibiting Multi-Functional ALDOA for Cancer Therapy
$498,144Garth Powis · Phusis Therapeutics, Inc. · R01 · FY2022 · CA
Definition of Immune Infiltrate Phenotype and DNA Damage Response Deficits Across Diverse Murine Mammary Carcinomas
$497,964Mary Helen Barcellos-Hoff · University Of California, San Francisco · R01 · FY2023 · CA
DKK2 regulates NK activation and tumor immunity
$497,913Dianqing Wu · Yale University · R01 · FY2019 · CA
Multiscale Computational Models Guided By Emerging Cellular Dynamics Quantification For Predicting Optimum Immune Checkpoint And Targeted Therapy Schedules
$497,777Trachette Jackson · University Of Michigan At Ann Arbor · U01 · FY2020 · CA
Project 2: Targeting signaling networks to overcome therapeutic resistance in pancreatic cancer
$497,575Tony R. Hunter · Salk Institute For Biological Studies · P01 · FY2025 · CA
Project 2: Targeting signaling networks to overcome therapeutic resistance in pancreatic cancer
$497,573Tony R. Hunter · Salk Institute For Biological Studies · P01 · FY2023 · CA
RNA editing in islet function and inflammation
$497,550Alvin Carter Powers · Vanderbilt University Medical Center · R01 · FY2024 · DK
Dissecting and Targeting MAPK - PPARG Crosstalk in Bladder Cancer
$497,544Kent W Mouw · Dana-Farber Cancer Inst · R01 · FY2024 · CA
Molecular mechanisms and therapeutic targeting of PI3K-p110beta/PTEN signaling in breast cancer and cancer immunity
$497,522Thomas M Roberts · Dana-Farber Cancer Inst · R01 · FY2019 · CA
Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas
$497,320George Yancey Gillespie · Treovir, Inc · R44 · FY2020 · CA
Role of Tspan5 in MHC I antigen presentation and cancer immune evasion
$497,167Kenneth L Rock · Univ Of Massachusetts Med Sch Worcester · R01 · FY2022 · AI
Novel DNA damage response therapeutics targeting replication protein A
$496,895John J Turchi · Indiana University Indianapolis · R01 · FY2022 · CA
Dissecting the NRG4 hormonal checkpoint in metabolic liver disease
$496,844Jiandie D Lin · University Of Michigan At Ann Arbor · R01 · FY2021 · DK
Harnessing the therapeutic potential of histotripsy focused ultrasound-induced immunogenic cancer cell death
$496,811Clifford Cho · Van Andel Research Institute · R01 · FY2025 · CA
Acute Kidney Injury and Double Negative T Cells
$496,786Abdel Hamad · Johns Hopkins University · R01 · FY2022 · DK
TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer
$496,381Gerardo Guillermo Mackenzie · University Of California At Davis · R01 · FY2024 · CA
TOWARD TRANSLATION OF NANFORMULATED PACLITAXEL-PLATINUM COMBINATION
$496,337Alexander V Kabanov · Univ Of North Carolina Chapel Hill · R01 · FY2023 · CA
TRAIL-induced Cell Death in Breast Cancer Cells
$496,310Stanley Lipkowitz · Division Of Clinical Sciences - Nci · ZIA · FY2015 · CA
Chitinase-3-like-1 mediated immunosuppression in Glioblastoma
$496,239Baoli Hu · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA
Project 1: Transgenic TCR-mediated tumor therapy
$496,050Philip D Greenberg · University Of Washington · P01 · FY2019 · CA
(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition
$495,996Iman Osman · New York University School Of Medicine · R01 · FY2021 · CA
Checkpoint Function of PTPalpha in Pathological Fibrogenesis in the Lung
$495,899Gregory Paul Downey · National Jewish Health · R01 · FY2018 · HL
Checkpoint Function of PTPalpha in Pathological Fibrogenesis in the Lung
$495,899Gregory Paul Downey · National Jewish Health · R01 · FY2019 · HL
Proteomic determinants of response to checkpoint blockade in malignant pleuralmesothelioma
$495,857Bryan Michael Burt · Baylor College Of Medicine · R37 · FY2023 · CA
Role of Tspan5 in MHC I antigen presentation and cancer immune evasion
$495,793Kenneth L Rock · Univ Of Massachusetts Med Sch Worcester · R01 · FY2023 · AI